Lecanemab winner in two categories at The Scrip Awards 2023 November 20, 2023 08:30 Non Regulatory Read more
Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today November 7, 2023 09:15 Regulatory Read more
LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period November 7, 2023 04:40 Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2023 on November 8 at 9.30 a.m. CET November 1, 2023 08:30 Non Regulatory Read more
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD October 25, 2023 23:25 Non Regulatory Read more
Lecanemab named one of the world’s best inventions in 2023 by TIME October 24, 2023 16:50 Non Regulatory Read more
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD October 16, 2023 08:00 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of September 29, 2023 September 29, 2023 18:00 Regulatory Read more
“LEQEMBI® Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan September 25, 2023 07:00 Regulatory Read more
BioArctic receives patent in Japan for new antibodies targeting Parkinson’s disease August 23, 2023 10:45 Non Regulatory Read more
Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference July 20, 2023 01:30 Non Regulatory Read more
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) 2023 July 12, 2023 01:30 Non Regulatory Read more
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease July 7, 2023 02:00 Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2023 on July 12 at 9.30 a.m. CET July 5, 2023 08:30 Non Regulatory Read more
FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease June 10, 2023 01:00 Regulatory Read more
Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease filed in South Korea June 8, 2023 01:30 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of May 31, 2023 May 31, 2023 18:00 Regulatory Read more
Marketing Authorisation Application for lecanemab submitted in Great Britain May 22, 2023 01:30 Non Regulatory Read more
Societal value of lecanemab in Japan published in Neurology and Therapy May 17, 2023 01:30 Non Regulatory Read more
Correction of press release: BioArctic repurchases employee stock options from CEO May 16, 2023 20:30 Regulatory Read more
Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer’s disease May 16, 2023 01:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2023 on April 27 at 9.30 a.m. CET April 19, 2023 08:30 Non Regulatory Read more
Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published April 4, 2023 01:30 Non Regulatory Read more
New lecanemab-data presented at the AD/PD™ 2023 conference April 3, 2023 08:00 Non Regulatory Read more
Eisai publishes additional detailed analyses from lecanemab phase 2b study March 31, 2023 08:00 Non Regulatory Read more
New lecanemab-data to be presented at the AD/PD™ 2023 conference March 23, 2023 08:00 Non Regulatory Read more
Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal March 20, 2023 00:30 Non Regulatory Read more
U.S. Veterans’ Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer’s disease March 13, 2023 20:30 Non Regulatory Read more
FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease and grants Priority Review March 6, 2023 00:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 28, 2023 February 28, 2023 18:00 Regulatory Read more
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration February 28, 2023 00:30 Non Regulatory Read more
The Nomination Committee’s proposal for the election of Board members and Chairman of the Board in BioArctic AB February 6, 2023 08:30 Regulatory Read more
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease January 27, 2023 00:30 Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET January 25, 2023 08:30 Non Regulatory Read more
BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election January 19, 2023 09:50 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in Japan January 16, 2023 01:30 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in the EU January 11, 2023 00:30 Regulatory Read more
BioArctic’s partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease January 7, 2023 05:30 Non Regulatory Read more
FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer’s disease January 6, 2023 20:30 Regulatory Read more
